Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

The pharmaceutical CDMO industry is consolidating

Find out why the pharmaceutical contract manufacturing market is heating up: M&A activity continues to rise. Get our new report: https://go.ey.com/2AIlfBr

  • Login to see the comments

  • Be the first to like this

The pharmaceutical CDMO industry is consolidating

  1. 1. The pharmaceutical contract manufacturing market is heating up: M&A activity continues to rise EY CDMO Study The pharmaceutical contract development and manufacturing (CDMO) market is heating up: three recent multi-billion dollar acquisitions of large players are just some examples for the rising M&A activity. At a time when Big Pharma, biotech and CDMO companies are reviewing their business models, the CDMO market offers considerable opportunities for current players as well as new entrants. 16.2 93 89 77 65 76 31% 63% 21% 28% 8.5 6% 2012 4.9 2013 51% 31% 2016 12% 33% 36% 67% 23% 2015 11.8 20% 2014 11% 10.9 65% Number of CDMO transactions (global) North America Europe Asia-Pacific Cumulative deal value (sum of EVs, US$b)

×